OXURION NV |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.0001 EUR | 0.00% |
|
0.00% | -88.89% |
| 04-12 | Oxurion NV Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
| 03-06 | Oxurion Raises Additional Funds from Convertible Bonds Issue | MT |
| Sales 2022 | 595K 636K 870K | Sales 2023 | 263K 281K 384K | Capitalization | 2.92M 3.13M 4.27M |
|---|---|---|---|---|---|
| Net income 2022 | -31M -33.15M -45.31M | Net income 2023 | -19M -20.32M -27.77M | EV / Sales 2022 | 20.6 x |
| Net Debt 2022 | 4.42M 4.73M 6.47M | Net Debt 2023 | 10.66M 11.4M 15.58M | EV / Sales 2023 | 51.6 x |
| P/E ratio 2022 |
-0.05
x | P/E ratio 2023 |
-0.08
x | Employees | 20 |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 90.08% |
More Fundamentals
* Assessed data
More news
More press releases
More news
| Current month | -50.00% | ||
| 3 months | -80.00% | ||
| 6 months | -85.71% | ||
| Current year | -88.89% |
1 week
0.00
0.00
1 month
0.000.00
Current year
0.000.00
1 year
0.000.01
3 years
0.002.69
5 years
0.006.78
10 years
0.0023.95
| Managers | Title | Age | Since |
|---|---|---|---|
Ghoson Pascal
CEO | Chief Executive Officer | - | 12-27 |
Andy de Deene
PRN | Corporate Officer/Principal | - | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Anat Loewenstein
BRD | Director/Board Member | 64 | 23-05-01 |
James Hartmann
BRD | Director/Board Member | 58 | 12-27 |
| Director/Board Member | - | 23-05-01 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-26 | 0.0001 | 0.00% | 12,307,000 |
| 24-04-25 | 0.0001 | 0.00% | 17,872,290 |
| 24-04-24 | 0.0001 | 0.00% | 11,810,580 |
| 24-04-23 | 0.0001 | 0.00% | 31,556,630 |
| 24-04-22 | 0.0001 | 0.00% | 38,940,700 |
Real-time Euronext Bruxelles, April 26, 2024 at 09:54 am
More quotes
Oxurion NV is a biopharmaceutical company developing next generation therapies, designed to improve and better preserve vision in patients with retinal disorders including Geographic Atrophy (GA), the leading cause of vision loss in elderly people worldwide.
Oxurion NV is aiming to build the leading global franchise in the treatment of Age-related macular degeneration (AMD), based on the successful clinical development of its two novel therapeutics: THR-149, a plasma kallikr
ein inhibitor being developed as a potential new standard of care for AMD patients who respond sub-optimally to anti-VEGF therapy, and THR-687, a pan-RGD integrin inhibitor, initially being developed as a potential new standard of care for all AMD patients.
Calendar
2024-05-15
- Annual General Meeting
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -88.89% | 614K | |
| +1.51% | 42.75B | |
| +8.57% | 41.34B | |
| +49.22% | 41.61B | |
| -12.36% | 26.59B | |
| +8.92% | 25.49B | |
| -25.13% | 18.12B | |
| +29.17% | 12.24B | |
| -3.12% | 11.76B | |
| +6.35% | 11B |
- Stock Market
- Equities
- OXUR Stock
